Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist

被引:31
作者
Davidson, Michael H. [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
NON-HDL CHOLESTEROL; EXENATIDE TWICE; BLOOD-PRESSURE; TYPE-2; PIOGLITAZONE; METAANALYSIS; EVENTS; SAFETY; ASSOCIATION; INHIBITORS;
D O I
10.1016/j.amjcard.2012.08.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In patients with diabetes mellitus (DM), a cardiovascular event is of critical concern because of the impact on long-term survival. Cardiovascular disease (CVD) is the leading cause of death for patients with DM, which makes the modification of risk factors in the patient with DM and CVD a primary focus of the preventive cardiologist. Management of this patient population should include pharmacologic interventions, such as antidyslipidemics (mainly statins) and oral anti-DM (or insulin) agents, as well as diet control, physical exercise, and smoking cessation. It is hoped that focus on the ABCs of treatment-hemoglobin A(1c), blood pressure, and cholesterol-lipid profile-along with ongoing and future studies on the effects of these interventions will help to reduce the significant morbidity and mortality from microvascular and macrovascular complications in these high-risk patients with DM. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110[suppl]:43B-49B)
引用
收藏
页码:43B / 49B
页数:7
相关论文
共 32 条
[11]   Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus [J].
Cushman, William C. ;
Evans, Gregory W. ;
Byington, Robert P. ;
Goff, David C., Jr. ;
Grimm, Richard H., Jr. ;
Cutler, Jeffrey A. ;
Simons-Morton, Denise G. ;
Basile, Jan N. ;
Corson, Marshall A. ;
Probstfield, Jeffrey L. ;
Katz, Lois ;
Peterson, Kevin A. ;
Friedewald, William T. ;
Buse, John B. ;
Bigger, J. Thomas ;
Gerstein, Hertzel C. ;
Ismail-Beigi, Faramarz .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) :1575-1585
[12]   EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DEFRONZO, RA ;
GOODMAN, AM ;
ABELOVE, W ;
REID, E ;
PITA, J ;
CALLAHAN, M ;
JOHNSON, D ;
PELAYO, E ;
PUGH, J ;
SHANK, M ;
GARZA, P ;
HAAG, B ;
KORFF, J ;
ANGELO, A ;
IZENSTEIN, B ;
VANDERLEEDEN, M ;
CATHCART, H ;
TIERNEY, M ;
BIGGS, D ;
KARAM, J ;
NOLTE, M ;
GAVIN, L ;
ELDER, MA ;
CORBOY, J ;
THWAITE, D ;
WONG, S ;
DAVIDSON, M ;
PETERS, A ;
DUNCAN, T ;
KERCHER, S ;
FISCHER, J ;
KIPNES, M ;
RADNICK, BJ ;
ROURA, M ;
ROQUE, J ;
MONTGOMERY, C ;
COLLUM, P ;
RUST, M ;
POHL, S ;
PFEIFER, M ;
ALLWEISS, P ;
LEICHTER, S ;
LEACH, P ;
GALLINA, D ;
MUSEY, V ;
BERKOWITZ, K ;
EASTMAN, R ;
TAYLOR, T ;
DELAPENA, MS ;
ZAWADSKI, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549
[13]   A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes [J].
Frederich, Robert ;
Alexander, John H. ;
Fiedorek, Fred T. ;
Donovan, Mark ;
Berglind, Niklas ;
Harris, Susan ;
Chen, Roland ;
Wolf, Robert ;
Mahaffey, Kenneth W. .
POSTGRADUATE MEDICINE, 2010, 122 (03) :16-27
[14]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[15]   GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP [J].
Green, Brian D. ;
Hand, Katharine V. ;
Dougan, Janette E. ;
McDonnell, Bronagh M. ;
Cassidy, Roslyn S. ;
Grieve, David J. .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 478 (02) :136-142
[16]   Favorable effects of pioglitazone and metformin compared with gliclazoide on lipoprotein subfractions in overweight patients with early type 2 diabetes [J].
Lawrence, JM ;
Reid, J ;
Taylor, GJ ;
Stirling, C ;
Recklees, JPD .
DIABETES CARE, 2004, 27 (01) :41-46
[17]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[18]   Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies [J].
Marso, Steven P. ;
Lindsey, Jason B. ;
Stolker, Joshua M. ;
House, John A. ;
Ravn, Gabriela Martinez ;
Kennedy, Kevin F. ;
Jensen, Troels M. ;
Buse, John B. .
DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (03) :237-240
[19]   Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes [J].
Matikainen, N. ;
Manttari, S. ;
Schweizer, A. ;
Ulvestad, A. ;
Mills, D. ;
Dunning, B. E. ;
Foley, J. E. ;
Taskinen, M. -R. .
DIABETOLOGIA, 2006, 49 (09) :2049-2057
[20]   Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes [J].
Mazzone, Theodore ;
Meyer, Peter M. ;
Kondos, George T. ;
Davidson, Michael H. ;
Feinstein, Steven B. ;
D'Agostino, Ralph B., Sr. ;
Perez, Alfonso ;
Haffner, Steven M. .
DIABETES, 2007, 56 (03) :849-855